Minimal change disease after COVID-19 vaccination

Kidney function can be impaired when there are problems with the glomeruli, the tiny units within the kidney where blood is cleaned. 

There have been a small but increasing number of cases of new-onset and relapse of glomerular diseases reported to have occurred in temporal association with the COVID-19 vaccines.

A new paper reports four such cases.

A 23-year-old woman with no significant past medical history presented with 5 days of generalized swelling and frothy urine 7 days after receiving her 2nd dose of the Moderna vaccine. She exhibited 3+ bilateral leg edema, mild periorbital edema, an elevated blood pressure of 150/80 mmHg, and a urine dipstick showing 4+ protein. Based on laboratory findings, the patient was diagnosed with Minimal change disease (MCD). The patient was started on a 1 mg/kg (70 mg) dose of oral prednisone together with a low dose of furosemide to help control her edema. Complete remission was achieved 4 weeks later. 

A 74-year-old Japanese man had a medical history that was significant only for hypertension. He was admitted with a 4-week history of edema and a 7-kg increase in body weight. He had received the 2nd injection of the Pfizer/BioNTech vaccine 2 days before the onset of edema. Spontaneous remission from nephrotic syndrome was observed ~ 6 weeks after the onset of symptoms.

A 72-year-old woman with hypertension, obesity, and dyslipidemia who developed foamy urine and peripheral edema 14 days after receiving the 1st dose of the AstraZeneca/ChAdOx1-S vaccine. The patient was discharged 6 days after initiation of corticosteroid therapy.

A 71-year-old male with prior history of acute myeloid leukemia and subsequent allogeneic hematopoietic stem cell transplantation (HSCT) in 2015, glucocorticoid-induced diabetes, nephrotic syndrome, mild Graft versus host disease (GVHD) in the liver and other health conditions, received the 2nd dose of Moderna/NIAID on April 12, 2021. Within a week of getting the 2nd dose, the patient noted foamy and dark urine, periorbital and leg edema as well as abdominal bloating. He received rituximab 1 g infusion on May 6 and May 19, 2021, and a short course of high dose prednisone as well loop diuretics with improvement. He took the booster on December 12, 2021 and did not notice any change in the color of his urine or foamy urine. 

READ MORE

Minimal change disease following vaccination with ChAdOx1 nCoV-19 vaccine was also documented in case of a young 24-year-old Indian male.


REFERENCE

Chandra P, Roldao M, Drachenberg C, Santos P, Washida N, Clark A, Bista B, Mitsuna R, Yango A. Minimal change disease and COVID-19 vaccination: Four cases and review of literature. Clinical Nephrology. Case Studies. 2022;10:54.

Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

COVID in May

Image
Concerns about a potential resurgence of COVID-19 are mounting as summer 2024 approaches.  This is driven by several indicators, including social media posts, healthcare data, and wastewater surveillance across different regions. Our study findings corroborate this trend.  While many forecasters anticipate a surge, others expect a gradual increase through the end of May, and then a decline again around early June. Reports from social media suggest emerging clusters of COVID-19 in Texas, several Canadian provinces, the UK, and on cruises in northern regions such as a Norwegian cruise to Alaska.  Data from Alberta's Respiratory virus dashboard   (total weekly laboratory-confirmed COVID-19 cases) and wastewater surveillance in Calgary indicate an uptick in COVID-19 cases starting April 2024. The most recent statistics from Alberta Health reveal a significant increase in hospitalizations due to COVID-19, with 114 individuals currently hospitalized—an increase of more than 20% over two
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high viral load
Read more